 | This article needs to be updated. (December 2015) |
| Clinical data | |
|---|---|
| Trade names | Provenge |
| Other names | APC8015 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a611025 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
  (what is this?) (verify) | |
Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP).[1][3][4] It is an autologous cellular immunotherapy.[1]
- ^ a b c "Provenge- sipuleucel-t injection". DailyMed. Retrieved 22 July 2021.
- ^ Cite error: The named reference
FDA Provengewas invoked but never defined (see the help page). - ^ Cite error: The named reference
Plosker_2011was invoked but never defined (see the help page). - ^ Cite error: The named reference
US6210662was invoked but never defined (see the help page).